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Diagnosing and prognosticating breast cancer has traditionally relied upon 
histomorphologic analysis and immunohistochemistry. With the recent advent of multi-
gene molecular assays, traditional methods are being augmented with molecular 
biomarkers. Implementation of the Oncotype DX assay has led to a change in treatment 
of patients with early stage, estrogen positive cancer. Oncotype DX uses the expression 
of 21 genes at the mRNA level to determine a 10 year recurrence risk in node negative 
and 5 year recurrence risk in node positive cancer. 16 malignancy markers related to 
estrogen, HER2, cell proliferation, and invasion potential are compared with 5 reference 
genes and run through a proprietary algorithm to provide a recurrence score of either low, 
intermediate, or high risk. Using the results of this assay provides an opportunity for 
personalized treatment based on unique malignancy markers. Oncotype DX allows 
patients with low recurrence risk to be spared the adverse effects of chemotherapy, while 
ensuring that high risk patients are treated systemically. For the first time, the most recent 
treatment guidelines specify the use of Oncotype DX for the management of breast 
cancer.  
 	  
